Technavio Announces the Publication of its Research Report Global Cervical Cancer Diagnostic Testing Market 2016-2020
Technavio recognizes the following companies as the key players in the global cervical cancer diagnostic testing market: Abbott Molecular, Becton, Dickinson & Company, Hologic, Qiagen, Quest Diagnostics, and Roche Molecular Diagnostics.
Other Prominent Vendors in the market are: Arbor Vita, Autogenomics, bioMérieux, BioVantra, Cancer Genetics, Cepheid, Cervia Diagnostics, Cytoimmun, DAAN Gene, Delphi Bioscience, DiaCarta, Fujirebio, Genera Biosystems, Greiner Bio-One, Guided Therapeutics, GynaeHealth, IncellDx, Micromedic Technologies, Norchip, OncoHealth, OralDNA Labs, Seegene, Solopap International, and Trovagene.
Browse full report with TOC @ https://marketreportscenter.com/reports/478775/global-cervical-cancer-diagnostic-testing-market-2016-2020
Commenting on the report, an analyst from Technavios team said: One trend in market is expansion into emerging markets. The global vendors are inclined upon penetrating the niche market of developing countries to maximize their revenue. In India, QIAGEN has careHPV test for serving women in low-resource areas, whereas digene HC2 HPV test serves women in areas having modern healthcare infrastructure. In 2009, the company entered into a partnership with Chittaranjan National Cancer Institute, in Kolkata, to establish a large-scale cervical cancer screening program. QIAGEN’s QIAGENcares, partners with PATH and Bill & Melinda Gates Foundation to improve the cervical cancer state worldwide. Not only that, QIAGEN collaborated with HPV vaccine developer Merck, to provide nearly five million free HPV vaccine doses and expanded the already existing HPV test donation program by 500,000 for screening a total of 1.5 million women in the emerging countries.
According to the report, one driver in the market is reimbursement policies. Most of the developed countries have specific agencies that have reimbursement policies to motivate and support women to undergo diagnostic tests. Agencies such as Wittenberg Weiner Consulting (WWC) and Wisconsin Well Women Program (WWWP) in the US reimburse an office visit for a pelvic exam, Pap smear test, HPV test, colposcopy, or other invasive diagnostic procedures, case management, and administrative fees. Similarly, diagnostic clinics have also started including cervical cancer diagnostics tests in their reimbursement policies. For Instance, Roche’s cobas HPV Test is covered by Selah Genomics in its own certified laboratory. These favorable reimbursements coupled with the government initiatives will drive the cervical cancer diagnostic testing market during the forecast period.
Further, the report states that one challenge in the market is rising awareness toward cervical cancer over-screening. The medical authorities worldwide suggest that HPV test should replace current Pap smear test as the primary cervical cancer screening. Till now, most of the governments in the developed countries recommended women, to undergo Pap smear test once in every two years. With the adoption of the HPV testing, which suggests women undergo the test once in every five years, not only the over-screening will be reduced, but also the governments can save on overall healthcare budgets. Based on Roches Athena clinical trial, the FDA acknowledged their cobas HPV test and recommended HPV testing as a replacement to Pap smear test.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/478775
About Cervical Cancer Diagnostic Testing
The global cervical cancer diagnostic testing market is growing steadily, primarily due to the availability and awareness of the programs in the developed countries. This test enables women aged 21 years and above to get screened, making most of the pre-cancerous lesions identifiable at stages when they can be treated easily. In the US, National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides low-cost even free cervical cancer screening for uninsured and low-income women. As per the Affordable Care Act, all health insurance plans initiated after September 23, 2010, should provide recommended cervical cancer screening tests to end-users. In developing countries, with the widespread awareness programs by public organizations like the WHO along with government initiatives, visual inspection with acetic acid (VIA) and Lugol’s iodine (VILI) are being performed to screen women. This initiative is expected to raise the market demand for cervical cancer screening and diagnostic tests.
Technavios analysts forecast the global cervical cancer diagnostic testing market to grow at a CAGR of 6.90% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cervical cancer diagnostic testing market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cervical cancer testing products used to perform cervical cancer screening.
The market is divided into the following segments based on geography:
Technavio’s report, Global Cervical Cancer Diagnostic Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
To Get Discount On The Report @ https://marketreportscenter.com/request-discount/478775
Connect for more details:
Market Reports Center